Sign in with your email address username.


[Articles] Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Doxorubicin does not need to be included in treatment of stage II–III intermediate risk Wilms’ tumour when the histological response to preoperative chemotherapy is incorporated into the risk stratification.